Publisher Correction: Safety and feasibility of CRISPR-edited T cells in patients with refractory non-small-cell lung cancer

Publisher Correction: Safety and feasibility of CRISPR-edited T cells in patients with refractory non-small-cell lung cancer

An amendment to this paper has been published and can be accessed via a link at the top of the paper.

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Nature medicine 2020-07, Vol.26 (7), p.1149-1149
Hauptverfasser: Lu, You, Xue, Jianxin, Deng, Tao, Zhou, Xiaojuan, Yu, Kun, Deng, Lei, Huang, Meijuan, Yi, Xin, Liang, Maozhi, Wang, Yu, Shen, Haige, Tong, Ruizhan, Wang, Wenbo, Li, Li, Song, Jin, Li, Jing, Su, Xiaoxing, Ding, Zhenyu, Gong, Youling, Zhu, Jiang, Wang, Yongsheng, Zou, Bingwen, Zhang, Yan, Li, Yanying, Zhou, Lin, Liu, Yongmei, Yu, Min, Wang, Yuqi, Zhang, Xuanwei, Yin, Limei, Xia, Xuefeng, Zeng, Yong, Zhou, Qiao, Ying, Binwu, Chen, Chong, Wei, Yuquan, Li, Weimin, Mok, Tony
Format: Artikel
Sprache:eng
Schlagworte:
631/1647/1511
692/308/2779/109/1940
692/699/67/1059/2325
692/699/67/1612/1350
Biomedical and Life Sciences
Biomedicine
Cancer Research
Infectious Diseases
Lung cancer
Lung cancer, Non-small cell
Metabolic Diseases
Molecular Medicine
Neurosciences
Publisher Correction
T cells
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:An amendment to this paper has been published and can be accessed via a link at the top of the paper.
ISSN:1078-8956
1546-170X
DOI:10.1038/s41591-020-0973-6